Summary

Location
at Irvine, California and other locations
Dates
study started
estimated completion

Description

Summary

The main purpose of this study is to characterize the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Official Title

An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis.

Keywords

Psoriasis BMS-986165

Eligibility

You can join if…

  • Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
  • Women must not be pregnant, lactating, or breastfeeding

You CAN'T join if...

  • Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
  • To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.

Locations

  • University California at Irvine Dermatology Clinical Research Center accepting new patients
    Irvine California 92697 United States
  • First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valley accepting new patients
    Fountain Valley California 92708 United States
  • Local Institution withdrawn
    Huntington Beach California 92647 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting Investigator Inquiry Form FDA Safety Alerts and Recalls
ID
NCT04036435
Phase
Phase 3
Study Type
Interventional
Last Updated